Shares of biopharmaceutical company IVERIC bio (NASDAQ:ISEE) are surging in the pre-market session today after the U.S. Food and Drug Administration granted a breakthrough therapy designation for its investigational complement C5 inhibitor avacincaptad pegol (ACP) for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Importantly, ACP is the only therapy to bag the designation for geographic atrophy. Further, the designation was based on 12-month primary endpoint data and enables accelerated development and regulatory review of the therapy.
The company is now focusing on a full NDA submission and market launch activities. Geographic atrophy is an advanced stage of AMD and causes an irreversible loss of vision.
Read full Disclosure